Skip to Main Content

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1

Conditions

Breast

Phase III

What is the purpose of this trial?

This study will compare DS 8201a to standard treatment.

Participants must have HER2 breast cancer that has been treated before.

Their cancer:

  • cannot be removed by an operation
  • has spread to other parts of the body

  • Trial with
    Daiichi Sankyo
  • Start Date
    07/01/2019
  • End Date
    01/31/2022
Trial Image

For more information about this study, contact:

Courtney Frederick

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    08/22/2019
  • Study HIC
    #2000024234